IL-1 belongs to a family of 11 members and is one of the seven receptor-agonists withpro-inflammatory activity. Beyond its biological role as a regulator of the innate immune response,IL-1 is involved in stress and chronic inflammation, therefore it is responsible for several pathologicalconditions. In particular, IL-1 is known to exert a critical function in malignancies, influencing thetumor microenvironment and promoting cancer initiation and progression. Thus, it orchestratesimmunosuppression recruiting pro-tumor immune cells of myeloid origin. Furthermore, new recentfindings showed that this cytokine can be directly produced by tumor cells in a positive feedback loopand contributes to the failure of targeted therapy. Activation of anti-apoptotic signaling pathwaysand senescence are some of the mechanisms recently proposed, but the role of IL-1 in tumor cellsrefractory to standard therapies needs to be further investigated.
Valerio Gelfo, Donatella Romaniello, Martina Mazzeschi, Michela Sgarzi, Giada Grilli, Alessandra Morselli, et al. (2020). Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(17), 1-14 [10.3390/ijms21176009].
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies
Valerio GelfoConceptualization
;Donatella RomanielloValidation
;Martina MazzeschiWriting – Review & Editing
;Michela SgarziWriting – Review & Editing
;Giada GrilliWriting – Review & Editing
;Beatrice ManzanWriting – Review & Editing
;Karim RihawiWriting – Review & Editing
;Mattia Lauriola
Supervision
2020
Abstract
IL-1 belongs to a family of 11 members and is one of the seven receptor-agonists withpro-inflammatory activity. Beyond its biological role as a regulator of the innate immune response,IL-1 is involved in stress and chronic inflammation, therefore it is responsible for several pathologicalconditions. In particular, IL-1 is known to exert a critical function in malignancies, influencing thetumor microenvironment and promoting cancer initiation and progression. Thus, it orchestratesimmunosuppression recruiting pro-tumor immune cells of myeloid origin. Furthermore, new recentfindings showed that this cytokine can be directly produced by tumor cells in a positive feedback loopand contributes to the failure of targeted therapy. Activation of anti-apoptotic signaling pathwaysand senescence are some of the mechanisms recently proposed, but the role of IL-1 in tumor cellsrefractory to standard therapies needs to be further investigated.File | Dimensione | Formato | |
---|---|---|---|
ijms-21-06009.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
839.43 kB
Formato
Adobe PDF
|
839.43 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.